Melanoma Focus Virtual Regional Meeting

Friday 13th May 2022

Organised by Dr Miranda Payne

Programme

09:00 - 09:15

Welcome/Introductions
Dr Mark Harries/Dr Miranda Payne/Susanna Daniels

09:15 - 10:00

Stage II Melanoma: Developments as a result from advances in systemic therapies

Associate Professor Alexander van Akkooi, Chair of Melanoma Surgery, Melanoma Institute of Australia

09:15 – 12:30

Pharma Exhibition Area / Posters

10:10 – 10:50

Virtual Networking:
My Melanoma: Mark Middleton

11:00 – 12:00

Pharma Sponsored Symposium: Novartis

Survivorship – A new treatment goal for advanced melanoma?

12:30 – 13:35

Session 1: Molecular surveillance of melanoma
Chair: Professor Mark Middleton – Professor of Experimental Cancer Medicine in the Department of Oncology, Consultant Medical Oncologist at the Oxford Cancer and Haematology Centre

12:30 – 12:55

Circulating tumour DNA; a new tool for the clinic
Dr Rebecca Lee, Clinical Lecturer in Medical Oncology, The University of Manchester

12:55 – 13:20

Biofluid metabolomics – the other liquid biopsy for cancer detection
Dr James Larkin, Lecturer in Biochemistry, Trinity College, Oxford

13:20 – 13:35

Q&A

13:35 – 14:35

Session 2: Living beyond a stage 4 diagnosis
Chair: Lesley Howells, Maggies Lead Psychologist, Maggies Centre, Oxford

13:35 – 14:15

Caroline Kohl (10 mins), Paul Duhig (10 mins), Dr Shelley Petzer (10 mins)

14:15 – 14:35

Q&A

14:35 – 14:45

Comfort Break

14:45 – 16:30

Session 3: Practice changes in oncology

Chair: Dr Ben Fairfax, Wellcome Intermediate Clinical Fellow and Honorary Consultant Medical Oncologist

14:45 – 15:10

Using Artificial Intelligence approaches to address an unmet need for melanoma
Dr Rubeta Matin, Consultant Dermatologist and Honorary Senior Clinical Lecturer, Oxford University Hospitals NHS Foundation Trust

15:10 – 15:35

Findings from the first UK Census of Skin Cancer Specialist Nurses
Dr Pippa Corrie, Consultant Medical Oncologist, Deeya Kotecha & Jashmitha Rammanohar, Final year medical students Addenbrooke’s Hospital, Cambridge

15:35 – 16:15

Melanoma immunotherapy: response and toxicity
Professor Genevieve Boland – Section Head, Melanoma/Sarcoma Surgery, Surgical Director, Termeer Center for Targeted Therapies, Director, Surgical Oncology, Research Laboratories, Massachusetts General Hospital, Associate Professor of Surgery, Harvard Medical School

16:15 – 16:30

Q&A

16:30 – 17:25

Session 4: MDT – Management of progression on adjuvant treatment (case-based discussions)
Chair: Dr Heather Shaw, Consultant Medical Oncologist, Mount Vernon Cancer Centre
Panel:
Mr Oliver Cassell, Consultant Plastic Surgeon, Oxford University Hospitals
Professor John Wagstaff, Professor of Medical Oncology, Swansea
Dr Steve Watkins, Consultant Oncologist, Birmingham University Hospitals
Professor Genevieve Boland, Section Head, Melanoma/Sarcoma Surgery, Surgical Director, Termeer Center for Targeted Therapies, Director, Surgical Oncology, Research Laboratories, Massachusetts General Hospital, Associate Professor of Surgery, Harvard Medical School

17:25 – 17:30

Concluding Remarks and Close
Dr Mark Harries, Chairman Melanoma Focus, Dr Miranda Payne, Organiser